Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson. Discuss the data presented at ASCO 2024 on the RELATIVITY-047 study of nivolumab plus relatlimab vs ...

RELATIVITY-047, a global, randomized, double-blind, phase II/III study, met its primary endpoint of progression-free survival (PFS). Relatlimab and nivolumab (RELA + NIVO) as a fixed-dose combination ...

Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...

Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial Nivolumab plus relatlimab ...

For untreated advanced melanoma, the fixed-dose combination of relatlimab and nivolumab is a "game changer that we have been waiting 10 years for," Hussein Tawbi, MD, PhD, University of Texas MD ...

(RTTNews) - Bristol Myers Squibb (BMY) today announced that primary endpoint was met in the phase II/III Relativity-047 study, a trial evaluating a fixed dose combination of company's anti-LAG-3 ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 2/3 RELATIVITY-047 trial, which showed that the fixed-dose combination of relatlimab, a LAG-3 ...

Relatlimab plus Opdivo improved progression-free survival in patients with untreated, advanced melanoma, and tended to have fewer side effects than other regimens used in this patient population.

Please provide your email address to receive an email when new articles are posted on . Relatlimab plus nivolumab continued to demonstrate a PFS benefit compared with nivolumab alone for patients with ...

Please provide your email address to receive an email when new articles are posted on . The addition of relatlimab to nivolumab conferred a significant PFS benefit among treatment-naive patients with ...